Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
NCT01728805
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
372
Enrollment
INDUSTRY
Sponsor class
Conditions
Cutaneous T-Cell Lymphoma
Interventions
BIOLOGICAL:
KW-0761
DRUG:
Vorinostat
Sponsor
Kyowa Kirin, Inc.